In fact, SGLT2 inhibitors have been shown to be well tolerated in patients with heart failure and chronic kidney disease (CKD), as demonstrated by extremely high participant retention rates in phase III clinical trials [37,38]. Here, SLC5A2 is linked to chronic kidney disease.